The World Health Organization warned that nicotine pouches are a threat, particularly to young people. The U.S. Food and Drug Administration has authorized them as reduced-risk products based on scientific review.
Two major health regulators have reached opposite conclusions about nicotine pouches. Both claim to be evidence-based.
This contradiction becomes even more striking when you examine what they actually agree on.
WHO and FDA both recognize a range of risks among tobacco products. Cigarettes (which burn tobacco) rank at the top as the most harmful, carrying the highest risk. Alternatives like nicotine pouches rank lower, carrying lower risks. This distinction appears in WHO's own guidance and FDA documentation.
Yet WHO’s 2026 campaign emphasizes nicotine pouches as a primary concern, particularly to young people. According to FDA data from the 2025 National Youth Tobacco Survey, youth nicotine pouch use remains low and stable at 1.7%, while overall youth tobacco use has declined during 2022-2025.
If regulators recognize that cigarettes are most harmful, shouldn't their warnings reflect that priority? Particularly when cigarettes remain the leading cause of tobacco harm?
The Maldives government has been following WHO guidance on tobacco policy. With illicit markets declining and consumption shifting to legal channels, the fiscal objective has been achieved.
But creating a legal market alone hasn't translated to the health improvements seen in other countries. Smoking rates remain high despite the shift to legal markets. So what's different about regulatory frameworks that actually achieve both fiscal AND health improvements?
Sweden offers a case study of what happens when regulatory decisions align with acknowledged risk differentiation.
Sweden's regulatory framework allows alternatives (nicotine pouches, vapes, snus) in regulated markets alongside tight restrictions on conventional cigarettes. The government taxes cigarettes heavily and alternatives lower, creating market signals about relative risk. Sweden is now considered smoke-free, with one of Europe's lowest smoking rates and lowest rates of smoking-related disease.
Sweden's outcomes suggest that when regulatory frameworks reflect the risk spectrum both WHO and FDA acknowledge, health results improve. But Sweden's approach mirrors FDA's evidence-based thinking more than WHO's current messaging priorities.
Which regulator is right? Or is the question itself the wrong one?
Perhaps the real question is: what does evidence about real-world health outcomes actually show when different regulatory approaches are implemented? As Maldives continues developing tobacco policies, which regulator's evidence should guide the next steps?
